These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 15282530)

  • 1. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
    Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Yang S; Darrow TL; Vervaert CE; Seigler HF
    Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
    J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
    Liu Z; Fan H; Wu Y; Chen B
    Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
    Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
    Moyer JS; Maine G; Mulé JJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1010-9. PubMed ID: 17084367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
    Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
    Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
    Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual role of dendritic cells in the induction and down-regulation of antigen-specific cutaneous inflammation.
    Krasteva M; Kehren J; Horand F; Akiba H; Choquet G; Ducluzeau MT; Tédone R; Garrigue JL; Kaiserlian D; Nicolas JF
    J Immunol; 1998 Feb; 160(3):1181-90. PubMed ID: 9570532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery.
    Asavaroengchai W; Kotera Y; Mulé JJ
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):931-6. PubMed ID: 11792864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
    Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.